Rallybio has completed a $145 million Series B financing. Proceeds from the financing will be used to advance Rallybio’s current portfolio of product candidates and further expand the Rallybio portfolio.
“The Rallybio team is highly motivated to bring our innovative product candidates to patients suffering from devastating rare disorders,” said Martin Mackay, Chairman and CEO of Rallybio.